-
A total of 342 Chinese Han discordant IS sib pairs consisting of 342 confirmed IS patients and 342 IS-free siblings were enrolled in the present study. The mean age at enrollment for IS patients was 61.09 ± 9.22. The mean age at enrollment for IS-free siblings was 57.52 ± 9.05. The mean age at onset for IS patients was 55.4 ± 9.09. Compared with IS-free siblings, IS patients were older, had a higher proportion of male, and had higher rates of diabetes mellitus and hypertension. IS patients also had higher smoking rate, as well as higher FBG levels, higher TG levels and lower HDL-C levels. The total adiponectin levels of IS patients were lower than IS-free siblings.
There were no significant differences with respect to alcohol consumption, BMI, TC, LDL-C, and HMW adiponectin levels between IS patients and IS-free siblings (Table 1).
Table 1. Anthropometric, Lifestyle Characteristics and Biochemical Indices of Ischemic Stroke Sib-pairs
Items IS IS-free Siblings P N 342 342 - Age 61.09 ± 9.22 57.52 ± 9.05 < 0.001^ Male 223 (65.20) 170 (49.71) < 0.001^ Diabetes mellitus 143 (41.81) 84 (24.56) < 0.001^ Hypertension 297 (86.84) 213 (62.28) < 0.001^ Smoker 203 (59.36) 150 (43.86) < 0.001^ Drinker 127 (37.13) 105 (30.70) 0.063 BMI 26.37 ± 3.57 26.18 ± 3.55 0.456 FBG 6.51 ± 2.78 5.98 ± 2.48 0.005^ TC 4.25 ± 1.23 4.27 ± 1.17 0.810 ln TG 0.49 ± 0.58 0.36 ± 0.62 0.002^ HDL-C 1.27 ± 0.44 1.40 ± 0.53 < 0.001^ LDL-C 2.87 ± 0.86 2.87 ± 0.81 0.969 ln total adiponectin 8.75 ± 0.89 8.92 ± 0.86 0.035^ ln HMW adiponectin 7.46 ± 0.74 7.54 ± 0.70 0.180 Note. Continuous variables were described as mean ± standard deviation. Categorical variables were described as frequency (proportion). IS: ischemic stroke; BMI: body mass index, kg/m2; FBG: fast blood glucose, mmol/L; TC: total cholesterol, mmol/L; ln TG: natural logarithmically transformed total triglycerides, mmol/L; HDL-C: high-density lipoprotein cholesterol, mmol/L; LDL-C: low-density lipoprotein cholesterol, mmol/L; ln total adiponectin: natural logarithmically transformed total adiponectin, ng/mL; ln HMW adiponectin: natural logarithmically transformed high-molecular weight adiponectin, ng/mL. ^P < 0.05. Associations between CDH13 SNPs and Adiponectin Levels In IS-free individuals, rs4783244 T allele was associated with total adiponectin levels (per T allele: Coef = -0.257: P = 0.001) but not HMW adiponectin levels (per T allele: Coef = -0.079 P = 0.204). Compared with rs4783244 GG genotype, GT/TT genotypes were associated with lower total adiponectin levels (GT/TT vs. GG: Coef = -0.265: P = 0.008).
In IS-free siblings, rs7193788 A allele was associated with total adiponectin levels (per A allele: Coef = -0.221: P = 0.001) and HMW adiponectin levels (per A allele: Coef = -0.163: P = 0.003). Compared with rs7193788 GG genotype, GA/AA genotypes were associated with lower total adiponectin levels (GA/AA vs. GG: Coef = -0.303: P = 0.006) and lower HMW adiponectin levels (GA/AA vs. GG: Coef = -0.222: P = 0.013). However, these associations were not found in IS patients (Table 2).
Table 2. Associations between CDH13 SNPs and Adiponectin Levels in IS patients and IS-free Siblings
SNP Genotype IS Patients IS-free Siblings Mean ± SD Coef P* Mean ± SD Coef P* Total adiponectin rs4783244 per T - -0.062 0.473 - -0.257 0.001^ GG 8.83 ± 0.97 Ref - 9.05 ± 0.91 Ref - GT/TT 8.69 ± 0.83 -0.137 0.241 8.83 ±0.82 -0.265 0.008^ rs7193788 per A - -0.086 0.302 - -0.221 0.001^ GG 8.98 ± 0.76 Ref - 9.00 ± 0.86 Ref - GA/AA 8.70 ± 0.93 -0.274 0.051 8.71 ± 0.85 -0.303 0.006^ HMW adiponectin rs4783244 per T - -0.034 0.649 - -0.079 0.204 GG 7.49 ± 0.74 Ref - 7.56 ± 0.76 Ref - GT/TT 7.43 ± 0.74 -0.063 0.529 7.53 ± 0.64 -0.073 0.366 rs7193788 per A - -0.017 0.816 - -0.163 0.003^ GG 7.46 ± 0.73 Ref - 7.61 ± 0.70 Ref - GA/AA 7.43 ± 0.81 -0.037 0.759 7.36 ± 0.66 -0.222 0.013^ Note. *Adjusting for age, sex, diabetes mellitus, hypertension, smoking status, drinking status, BMI, ln TG, HDL-C. HMW adiponectin: high-molecular weight adiponectin. ^P < 0.05. Associations between CDH13 SNPs and Ischemic Stroke CDH13 rs7193788 was significantly associated with IS after Bonferroni correction (α = 0.025). Compared with individuals of rs7193788 GG genotype, those of GA/AA genotypes had higher risks of IS (GA/AA vs. GG: unadjusted: OR = 1.48: 95% CI: 1.05-2.09: P = 0.025, adjusted: OR = 1.55: 95% CI: 1.07-2.24: P = 0.020). No association was found between rs4783244 and IS (Table 3).
Table 3. Associations between CDH13 SNPs and Ischemic Stroke
SNP Location MAF HWE P-Value Genotype Unadjusted Adjusted* OR 95% CI P OR 95% CI P rs4783244 16:82628663 T (0.348) 0.818 GG Ref - - Ref - - GT/TT 1.05 0.79: 1.40 0.736 1.09 0.80: 1.49 0.582 rs7193788 16:82622555 G (0.478) 0.666 GG Ref - - Ref - - GA/AA 1.48 1.05: 2.09 0.025^ 1.55 1.07: 2.24 0.020^ Note. *Adjusting for age, sex, diabetes mellitus, hypertension, smoking status, drinking status, BMI, lnTG, HDL-C. MAF: minor allele frequency. ^P < 0.05. Interactions between CDH13 SNPs and Other Risk Factors for IS We investigated interactions between 2 CDH13 SNPs and smoking, drinking, BMI, history of hypertension, history of diabetes for IS. We observed a statistically significant interaction between CDH13 rs7193788 and diabetes (P = 0.036). Compared to diabetes-free individuals with rs7193788 GG genotype, diabetes patients with rs7193788 GA/AA genotypes had higher risks for IS (unadjusted: OR = 3.17: 95% CI: 1.96-5.12: P < 0.001, adjusted: OR = 2.64: 95% CI: 1.58-4.40: P < 0.001)
No interaction was found between CDH13 rs4783244 and diabetes for IS (P = 0.268). However, compared to diabetes-free individuals with rs4783244 GG genotype, diabetes patients with rs4783244 GT/TT genotypes had higher risks for IS (Unadjusted: OR = 2.50: 95% CI: 1.62-3.86: P < 0.001, adjusted: OR = 2.03: 95% CI: 1.27-3.24: P = 0.003) (Table 4).
Table 4. Interactions between CDH13 SNPs and Diabetes for Ischemic Stroke
Diabetes Genotype Unadjusted Adjusted P for Interaction OR 95% CI P* OR 95% CI P* rs4783244 No GG Ref - - Ref - - 0.268 GT/TT 0.96 0.67: 1.37 0.825 0.99 0.67: 1.45 0.941 Yes GG 1.78 1.12: 2.83 0.015^ 1.53 0.93: 2.52 0.092 GT/TT 2.50 1.62: 3.86 < 0.001^ 2.03 1.27: 3.24 0.003^ rs7193788 No GG Ref - - Ref - - 0.036^ GA/AA 1.19 0.78: 1.83 0.421 1.20 0.76: 1.89 0.425 Yes GG 1.30 0.68: 2.46 0.424 1.12 0.57: 2.21 0.735 GA/AA 3.17 1.96: 5.12 < 0.001^ 2.64 1.58: 4.40 < 0.001^ Adjusting for age, sex, hypertension, smoking status, drinking status, BMI, lnTG, HDL-C. ^P < 0.05.
doi: 10.3967/bes2017.004
CDH13 Genetic Polymorphisms, Adiponectin and Ischemic Stroke: a Chinese Family-based Sib-pair Study
-
Abstract:
Objective To understand the relationships between CDH13 (T-cadherin) genetic polymorphisms, adiponectin levels and ischemic stroke, and possible interactions between CDH13 polymorphisms and other risk factors. Methods We recruited 342 Chinese ischemic stroke sib pairs. We genotyped rs4783244 and rs7193788 on CDH13 using time-of-flight mass spectrometry genotyping technology and measured total and high-molecular weight (HMW) adiponectin levels. We investigated associations between SNPs and ischemic stroke, and interactions between SNPs and other risk factors using multi-level mixed-effects regression model. Results In individuals without ischemic stroke, CDH13 rs4783244 was associated with total adiponectin levels (per T:Coef=-0.257, P=0.001). CDH13 rs7193788 was associated with total adiponectin levels (per A:Coef=-0.221, P=0.001) and HMW adiponectin levels (per A:Coef=-0.163, P=0.003). rs7193788 was significantly associated with ischemic stroke (GA/AA vs. GG:OR=1.55, 95% CI:1.07 to 2.24, P=0.020) after Bonferroni correction (α=0.025). There was an interaction between rs7193788 and diabetes (P=0.036). Compared to diabetes-free individuals with rs7193788 GG genotype, diabetes patients with rs7193788 GA/AA genotypes had higher risks for ischemic stroke (OR=2.64, 95% CI:1.58-4.40, P<0.001). Conclusion CDH13 genetic polymorphisms are associated with adiponectin levels and ischemic stroke. An interaction is found between CDH13 SNP and diabetes for ischemic stroke. -
Key words:
- CDH13 /
- Genetic polymorphisms /
- Adiponectin /
- Ischemic stroke /
- Sib pair
-
Table 1. Anthropometric, Lifestyle Characteristics and Biochemical Indices of Ischemic Stroke Sib-pairs
Items IS IS-free Siblings P N 342 342 - Age 61.09 ± 9.22 57.52 ± 9.05 < 0.001^ Male 223 (65.20) 170 (49.71) < 0.001^ Diabetes mellitus 143 (41.81) 84 (24.56) < 0.001^ Hypertension 297 (86.84) 213 (62.28) < 0.001^ Smoker 203 (59.36) 150 (43.86) < 0.001^ Drinker 127 (37.13) 105 (30.70) 0.063 BMI 26.37 ± 3.57 26.18 ± 3.55 0.456 FBG 6.51 ± 2.78 5.98 ± 2.48 0.005^ TC 4.25 ± 1.23 4.27 ± 1.17 0.810 ln TG 0.49 ± 0.58 0.36 ± 0.62 0.002^ HDL-C 1.27 ± 0.44 1.40 ± 0.53 < 0.001^ LDL-C 2.87 ± 0.86 2.87 ± 0.81 0.969 ln total adiponectin 8.75 ± 0.89 8.92 ± 0.86 0.035^ ln HMW adiponectin 7.46 ± 0.74 7.54 ± 0.70 0.180 Note. Continuous variables were described as mean ± standard deviation. Categorical variables were described as frequency (proportion). IS: ischemic stroke; BMI: body mass index, kg/m2; FBG: fast blood glucose, mmol/L; TC: total cholesterol, mmol/L; ln TG: natural logarithmically transformed total triglycerides, mmol/L; HDL-C: high-density lipoprotein cholesterol, mmol/L; LDL-C: low-density lipoprotein cholesterol, mmol/L; ln total adiponectin: natural logarithmically transformed total adiponectin, ng/mL; ln HMW adiponectin: natural logarithmically transformed high-molecular weight adiponectin, ng/mL. ^P < 0.05. Table 2. Associations between CDH13 SNPs and Adiponectin Levels in IS patients and IS-free Siblings
SNP Genotype IS Patients IS-free Siblings Mean ± SD Coef P* Mean ± SD Coef P* Total adiponectin rs4783244 per T - -0.062 0.473 - -0.257 0.001^ GG 8.83 ± 0.97 Ref - 9.05 ± 0.91 Ref - GT/TT 8.69 ± 0.83 -0.137 0.241 8.83 ±0.82 -0.265 0.008^ rs7193788 per A - -0.086 0.302 - -0.221 0.001^ GG 8.98 ± 0.76 Ref - 9.00 ± 0.86 Ref - GA/AA 8.70 ± 0.93 -0.274 0.051 8.71 ± 0.85 -0.303 0.006^ HMW adiponectin rs4783244 per T - -0.034 0.649 - -0.079 0.204 GG 7.49 ± 0.74 Ref - 7.56 ± 0.76 Ref - GT/TT 7.43 ± 0.74 -0.063 0.529 7.53 ± 0.64 -0.073 0.366 rs7193788 per A - -0.017 0.816 - -0.163 0.003^ GG 7.46 ± 0.73 Ref - 7.61 ± 0.70 Ref - GA/AA 7.43 ± 0.81 -0.037 0.759 7.36 ± 0.66 -0.222 0.013^ Note. *Adjusting for age, sex, diabetes mellitus, hypertension, smoking status, drinking status, BMI, ln TG, HDL-C. HMW adiponectin: high-molecular weight adiponectin. ^P < 0.05. Table 3. Associations between CDH13 SNPs and Ischemic Stroke
SNP Location MAF HWE P-Value Genotype Unadjusted Adjusted* OR 95% CI P OR 95% CI P rs4783244 16:82628663 T (0.348) 0.818 GG Ref - - Ref - - GT/TT 1.05 0.79: 1.40 0.736 1.09 0.80: 1.49 0.582 rs7193788 16:82622555 G (0.478) 0.666 GG Ref - - Ref - - GA/AA 1.48 1.05: 2.09 0.025^ 1.55 1.07: 2.24 0.020^ Note. *Adjusting for age, sex, diabetes mellitus, hypertension, smoking status, drinking status, BMI, lnTG, HDL-C. MAF: minor allele frequency. ^P < 0.05. Table 4. Interactions between CDH13 SNPs and Diabetes for Ischemic Stroke
Diabetes Genotype Unadjusted Adjusted P for Interaction OR 95% CI P* OR 95% CI P* rs4783244 No GG Ref - - Ref - - 0.268 GT/TT 0.96 0.67: 1.37 0.825 0.99 0.67: 1.45 0.941 Yes GG 1.78 1.12: 2.83 0.015^ 1.53 0.93: 2.52 0.092 GT/TT 2.50 1.62: 3.86 < 0.001^ 2.03 1.27: 3.24 0.003^ rs7193788 No GG Ref - - Ref - - 0.036^ GA/AA 1.19 0.78: 1.83 0.421 1.20 0.76: 1.89 0.425 Yes GG 1.30 0.68: 2.46 0.424 1.12 0.57: 2.21 0.735 GA/AA 3.17 1.96: 5.12 < 0.001^ 2.64 1.58: 4.40 < 0.001^ Adjusting for age, sex, hypertension, smoking status, drinking status, BMI, lnTG, HDL-C. ^P < 0.05. -
[1] Mendis S, Davis S, Norrving B. Organizational update the world health organization global status report on noncommunicable diseases 2014; one more landmark step in the combat against stroke and vascular disease. Stroke, 2015; 46, e121-e2. doi: 10.1161/STROKEAHA.115.008097 [2] Feigin VL, Krishnamurthi RV, Parmar P, et al. Update on the global burden of ischemic and hemorrhagic stroke in 1990-2013:the GBD 2013 study. Neuroepidemiology, 2015; 45, 161-76. doi: 10.1159/000441085 [3] Zhao D, Liu J, Wang W, et al. Epidemiological transition of stroke in China twenty-one-year observational study from the sino-MONICA-Beijing project. Stroke, 2008; 39, 1668-74. doi: 10.1161/STROKEAHA.107.502807 [4] Antoniades C, Antonopoulos AS, Tousoulis D, et al. Adiponectin:from obesity to cardiovascular disease. Obes Rev, 2009; 10, 269-79. doi: 10.1111/obr.2009.10.issue-3 [5] Kazumi T, Kawaguchi A, Sakai K, et al. Young men with high-normal blood pressure have lower serum adiponectin, smaller LDL size, and higher elevated heart rate than those with optimal blood pressure. Diabetes Care, 2002; 25, 971-6. doi: 10.2337/diacare.25.6.971 [6] Pischon T, Hu FB, Girman CJ, et al. Plasma total and high molecular weight adiponectin levels and risk of coronary heart disease in women. Atherosclerosis, 2011; 219, 322-9. doi: 10.1016/j.atherosclerosis.2011.07.011 [7] Ouchi N, Kihara S, Funahashi T, et al. Obesity, adiponectin and vascular inflammatory disease. Curr Opin Lipidol, 2003; 14, 561-6. doi: 10.1097/00041433-200312000-00003 [8] Tan KC, Xu A, Chow WS, et al. Hypoadiponectinemia is associated with impaired endothelium-dependent vasodilation. J Clin Endocrinol Metab, 2004; 89, 765-9. doi: 10.1210/jc.2003-031012 [9] Nishimura M, Izumiya Y, Higuchi A, et al. Adiponectin prevents cerebral ischemic injury through endothelial nitric oxide synthase dependent mechanisms. Circulation, 2008; 117, 216-23. doi: 10.1161/CIRCULATIONAHA.107.725044 [10] Savopoulos C, Michalakis K, Apostolopoulou M, et al. Adipokines and stroke:a review of the literature. Maturitas, 2011; 70, 322-7. doi: 10.1016/j.maturitas.2011.09.002 [11] Ling H, Waterworth DM, Stirnadel HA, et al. Genome-wide Linkage and Association Analyses to Identify Genes Influencing Adiponectin Levels:The GEMS Stud. Obesity, 2009; 17, 737-44. doi: 10.1038/oby.2008.625 [12] Richards JB, Waterworth D, O'Rahilly S, et al. A genome-wide association study reveals variants in ARL15 that influence adiponectin levels. PLoS Genet, 2009; 5, e1000768. doi: 10.1371/journal.pgen.1000768 [13] Qi L, Menzaghi C, Salvemini L, et al. Novel locus FER is associated with serum HMW adiponectin levels. Diabetes, 2011; 60, 2197-201. doi: 10.2337/db10-1645 [14] Wu Y, Li Y, Lange EM, et al. Genome-wide association study for adiponectin levels in Filipino women identifies CDH13 and a novel uncommon haplotype at KNG1-ADIPOQ. Human molecular genetics, 2010; 19, 4955-64. doi: 10.1093/hmg/ddq423 [15] Jee SH, Sull JW, Lee JE, et al. Adiponectin concentrations:a genome-wide association study. Am J Hum Genet, 2010; 87, 545-52. doi: 10.1016/j.ajhg.2010.09.004 [16] Morisaki H, Yamanaka I, Iwai N, et al. CDH13 gene coding T-cadherin influences variations in plasma adiponectin levels in the Japanese population. Hum Mutat, 2012; 33, 402-10. doi: 10.1002/humu.21652 [17] Chung CM, Lin TH, Chen JW, et al. A genome-wide association study reveals a quantitative trait locus of adiponectin on CDH13 that predicts cardiometabolic outcomes. Diabetes, 2011; 60, 2417-23. doi: 10.2337/db10-1321 [18] Gao H, Kim YM, Chen P, et al. Genetic variation in CDH13 is associated with lower plasma adiponectin levels but greater adiponectin sensitivity in East Asian populations. Diabetes, 2013; 62, 4277-83. doi: 10.2337/db13-0129 [19] Takeuchi T, Adachi Y, Ohtsuki Y, et al. Adiponectin receptors, with special focus on the role of the third receptor, T-cadherin, in vascular disease. Med Mol Morphol, 2007; 40, 115-20. doi: 10.1007/s00795-007-0364-9 [20] Hug C, Wang J, Ahmad NS, et al. T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc Natl Acad Sci U S A, 2004; 101, 10308-13. doi: 10.1073/pnas.0403382101 [21] Cheong MY, Bang OS, Cha MH, et al. Association of the adiponectin gene variations with risk of ischemic stroke in a Korean population. Yonsei Med J, 2011; 52, 20-5. doi: 10.3349/ymj.2011.52.1.20 [22] Reich DE, Goldstein DB. Detecting association in a case-control study while correcting for population stratification. Genetic epidemiology, 2001; 20, 4-16. doi: 10.1002/(ISSN)1098-2272 [23] Cordell HJ, Clayton DG. Genetic association studies. The Lancet, 2005; 366, 1121-31. doi: 10.1016/S0140-6736(05)67424-7 [24] Tang X, Hu Y, Chen D, et al. The Fangshan/family-based Ischemic Stroke Study In China (FISSIC) protocol. BMC Med Genet, 2007; 8, 60. https://www.researchgate.net/publication/6015551_The_Fangshanfamily-based_ischemic_stroke_study_in_China_FISSIC_protocol [25] Meschia JF, Brown RD Jr, Brott TG, et al. The Siblings With Ischemic Stroke Study (SWISS) protocol. BMC Med Genet, 2002; 3, 1. http://www.biomedcentral.com/imedia/122285541541584_manuscript.pdf [26] Jones WJ, Williams LS, Meschia JF. Validating the Questionnaire for Verifying Stroke-Free Status (QVSFS) by neurological history and examination. Stroke, 2001; 32, 2232-6. doi: 10.1161/hs1001.096191 [27] Meschia JF, Lojacono MA, Miller MJ, et al. Reliability of the questionnaire for verifying stroke-free status. Cerebrovasc Dis, 2004; 17, 218-23. https://www.researchgate.net/publication/8933412_Reliability_of_the_Questionnaire_for_Verifying_Stroke-Free_Status [28] Gupta V, Vinay DG, Sovio U, et al. Association study of 25 type 2 diabetes related loci with measures of obesity in Indian sib pairs. PLoS One, 2013; 8, e53944. doi: 10.1371/journal.pone.0053944 [29] Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med, 2001; 7, 941-6. doi: 10.1038/90984 [30] Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol, 2000; 20, 1595-9. doi: 10.1161/01.ATV.20.6.1595 [31] Pajvani UB, Du X, Combs TP, et al. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications fpr metabolic regulation and bioactivity. J Biol Chem, 2003; 278, 9073-85. doi: 10.1074/jbc.M207198200 [32] Fisher FM, Trujillo ME, Hanif W, et al. Serum high molecular weight complex of adiponectin correlates better with glucose tolerance than total serum adiponectin in Indo-Asian males. Diabetologia, 2005; 48, 1084-7. doi: 10.1007/s00125-005-1758-7 [33] Pajvani UB, Hawkins M, Combs TP, et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem, 2004; 279, 12152-62. doi: 10.1074/jbc.M311113200 [34] Otsuka I, Watanabe Y, Hishimoto A, et al. Association analysis of the Cadherin13 gene with schizophrenia in the Japanese population. Neuropsychiatr Dis Treat, 2015; 11, 1381-93. https://www.researchgate.net/publication/278793425_Association_analysis_of_the_Cadherin13_gene_with_schizophrenia_in_the_Japanese_population [35] Arregui M, Buijsse B, Fritsche A, et al. Adiponectin and risk of stroke:prospective study and meta-analysis. Stroke, 2014; 45, 10-7. doi: 10.1161/STROKEAHA.113.001851 [36] Matsumoto M, Ishikawa S, Kajii E. Association of adiponectin with cerebrovascular disease:a nested case-control study. Stroke, 2008; 39, 323-8. doi: 10.1161/STROKEAHA.107.497552 [37] Bidulescu A, Liu J, Chen Z, et al. Associations of adiponectin and leptin with incident coronary heart disease and ischemic stroke in african americans:the jackson heart study. Front Public Health, 2013; 1, 16. [38] Hao G, Li W, Guo R, et al. Serum total adiponectin level and the risk of cardiovascular disease in general population:a meta-analysis of 17 prospective studies. Atherosclerosis, 2013; 228, 29-35. doi: 10.1016/j.atherosclerosis.2013.02.018 [39] Kanhai DA, Kranendonk ME, Uiterwaal CS, et al. Adiponectin and incident coronary heart disease and stroke. A systematic review and meta-analysis of prospective studies. Obes Rev, 2013; 14, 555-67. doi: 10.1111/obr.2013.14.issue-7 [40] Soderberg S, Stegmayr B, Stenlund H, et al. Leptin, but not adiponectin, predicts stroke in males. J Intern Med, 2004; 256, 128-36. doi: 10.1111/jim.2004.256.issue-2 [41] Hegener HH, Lee IM, Cook NR, et al. Association of adiponectin gene variations with risk of incident myocardial infarction and ischemic stroke:a nested case-control study. Clin Chem, 2006; 52, 2021-7. doi: 10.1373/clinchem.2006.074476 [42] Liu F, He Z, Deng S, et al. Association of adiponectin gene polymorphisms with the risk of ischemic stroke in a Chinese Han population. Mol Biol Rep, 2011; 38, 1983-8. doi: 10.1007/s11033-010-0320-y [43] Jo J, Sull JW, Park EJ, et al. Effects of smoking and obesity on the association between CDH13 (rs3865188) and adiponectin among Korean men:the KARE study. Obesity (Silver Spring), 2012; 20, 1683-7. doi: 10.1038/oby.2011.128 [44] Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis:epidemiology, pathophysiology, and management. Jama, 2002; 287, 2570-81. doi: 10.1001/jama.287.19.2570 [45] Kuusisto J, Mykkanen L, Pyorala K, et al. Non-insulin-dependent diabetes and its metabolic control are important predictors of stroke in elderly subjects. Stroke, 1994; 25, 1157-64. doi: 10.1161/01.STR.25.6.1157 [46] Folsom AR, Rasmussen ML, Chambless LE, et al. Prospective associations of fasting insulin, body fat distribution, and diabetes with risk of ischemic stroke. The atherosclerosis risk in communities (ARIC) study investigators. Diabetes Care, 1999; 22, 1077-83. doi: 10.2337/diacare.22.7.1077 [47] Ouedraogo R, Gong Y, Berzins B, et al. Adiponectin deficiency increases leukocyte-endothelium interactions via upregulation of endothelial cell adhesion molecules in vivo. J Clin Invest, 2007; 117, 1718-26. doi: 10.1172/JCI29623 [48] Laird NM, Lange C. Family-based designs in the age of large-scale gene-association studies. Nat Rev Genet, 2006; 7, 385-94. [49] Kim BJ, Lee SH, Ryu WS, et al. Adipocytokines and ischemic stroke:differential associations between stroke subtypes. J Neurol Sci, 2012; 312, 117-22. doi: 10.1016/j.jns.2011.08.007